1. Home
  2. XLO vs ACCS Comparison

XLO vs ACCS Comparison

Compare XLO & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

41.8M

Sector

Health Care

ML Signal

HOLD

ACCS

ACCESS Newswire Inc.

N/A

Current Price

$9.01

Market Cap

35.8M

ML Signal

N/A

Company Overview

Basic Information
Metric
XLO
ACCS
Founded
2016
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Publishing
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
41.8M
35.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
XLO
ACCS
Price
$0.65
$9.01
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.00
$14.00
AVG Volume (30 Days)
528.0K
16.7K
Earning Date
11-13-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$31,804,000.00
$22,646,000.00
Revenue This Year
$589.60
$0.18
Revenue Next Year
$38.00
$7.16
P/E Ratio
N/A
N/A
Revenue Growth
588.40
42.30
52 Week Low
$0.62
$7.72
52 Week High
$1.70
$13.35

Technical Indicators

Market Signals
Indicator
XLO
ACCS
Relative Strength Index (RSI) 32.82 49.52
Support Level $0.68 $8.75
Resistance Level $0.73 $9.30
Average True Range (ATR) 0.04 0.43
MACD -0.01 0.13
Stochastic Oscillator 10.24 64.51

Price Performance

Historical Comparison
XLO
ACCS

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

About ACCS ACCESS Newswire Inc.

ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.

Share on Social Networks: